Review



rotem® delta analyser  (Pentapharm)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Pentapharm rotem® delta analyser
    -hALPCs PCA in <t>ROTEM</t> (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Rotem® Delta Analyser, supplied by Pentapharm, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rotem%C2%AE+delta+analyser/rotem++delta+analyser/pmc03416788-155-5-8
    Average 90 stars, based on 1 article reviews
    rotem® delta analyser - by Bioz Stars, 2026-09
    90/100 stars

    Images

    1) Product Images from "Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity"

    Article Title: Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity

    Journal: PLoS ONE

    doi: 10.1371/journal.pone.0042819

    -hALPCs PCA in ROTEM (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Figure Legend Snippet: -hALPCs PCA in ROTEM (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).

    Techniques Used: Coagulation, Incubation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with human adult liver progenitor cells (hALPCs), hepatocytes, skin fibroblasts, bone marrow mesenchymal stem cells (BMMSC), bone marrow haematopoietic stem cells (BMHSC), or liver myofibroblasts suspended in human albumin 5% f as compared to control.
    Figure Legend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with human adult liver progenitor cells (hALPCs), hepatocytes, skin fibroblasts, bone marrow mesenchymal stem cells (BMMSC), bone marrow haematopoietic stem cells (BMHSC), or liver myofibroblasts suspended in human albumin 5% f as compared to control.

    Techniques Used: Coagulation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) deficient in coagulation factors VII, V, X, and II (7d Pl, 5d Pl, 10d Pl, and 2d Pl, respectively) in presence of cells suspended in human albumin 5%. Human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to normal plasma f as compared to control.
    Figure Legend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) deficient in coagulation factors VII, V, X, and II (7d Pl, 5d Pl, 10d Pl, and 2d Pl, respectively) in presence of cells suspended in human albumin 5%. Human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to normal plasma f as compared to control.

    Techniques Used: Coagulation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with or without hepatocytes suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control.
    Figure Legend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with or without hepatocytes suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control.

    Techniques Used: Coagulation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control $ as compared to bivalirudin Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control $ as compared to bivalirudin.
    Figure Legend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control $ as compared to bivalirudin Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control $ as compared to bivalirudin.

    Techniques Used: Coagulation



    Similar Products

    rotem® delta analyser  (Pentapharm)
    90
    Pentapharm rotem® delta analyser
    -hALPCs PCA in <t>ROTEM</t> (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Rotem® Delta Analyser, supplied by Pentapharm, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rotem%C2%AE+delta+analyser/rotem++delta+analyser/pmc03416788-155-5-8
    Average 90 stars, based on 1 article reviews
    rotem® delta analyser - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rotem delta analyser  (TEM International)
    90
    TEM International rotem delta analyser
    -hALPCs PCA in <t>ROTEM</t> (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Rotem Delta Analyser, supplied by TEM International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rotem%C2%AE+delta+analyser/rotem+delta+analyzers/pm34528253-56-5-8
    Average 90 stars, based on 1 article reviews
    rotem delta analyser - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rotem® delta analyser  (Rotem Industries)
    90
    Rotem Industries rotem® delta analyser
    -hALPCs PCA in <t>ROTEM</t> (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Rotem® Delta Analyser, supplied by Rotem Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rotem%C2%AE+delta+analyser/rotem++delta+analyser/pm32114247-0-18-18
    Average 90 stars, based on 1 article reviews
    rotem® delta analyser - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rotem delta analyser  (Rotem Industries)
    90
    Rotem Industries rotem delta analyser
    -hALPCs PCA in <t>ROTEM</t> (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Rotem Delta Analyser, supplied by Rotem Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rotem%C2%AE+delta+analyser/rotem++delta+analyser/pm32114247-14-21-21
    Average 90 stars, based on 1 article reviews
    rotem delta analyser - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rotem® delta analyser  (TEM International)
    90
    TEM International rotem® delta analyser
    -hALPCs PCA in <t>ROTEM</t> (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Rotem® Delta Analyser, supplied by TEM International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rotem%C2%AE+delta+analyser/rotem+delta+analyzers/pm30831006-29-11-14
    Average 90 stars, based on 1 article reviews
    rotem® delta analyser - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    rotem-coagulation analyser rotem delta  (Rotem Industries)
    90
    Rotem Industries rotem-coagulation analyser rotem delta
    -hALPCs PCA in <t>ROTEM</t> (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).
    Rotem Coagulation Analyser Rotem Delta, supplied by Rotem Industries, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rotem%C2%AE+delta+analyser/rotem++delta+analyser/pmc06329185-56-8-10
    Average 90 stars, based on 1 article reviews
    rotem-coagulation analyser rotem delta - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    -hALPCs PCA in ROTEM (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).

    Journal: PLoS ONE

    Article Title: Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity

    doi: 10.1371/journal.pone.0042819

    Figure Lengend Snippet: -hALPCs PCA in ROTEM (Blood). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation was induced in the absence of recalcification. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCs PCA in ROTEM (Plasma). Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) obtained from blood incubated in presence or not of cells suspended in human albumin 5%. Hepatocytes (white), human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to hALPCs f as compared to control hALPCs vs. hepatocytes vs. control. ***p<0.001 (Kruskal-Wallis test). -hALPCS PCA in ROTEM (no TF addition). Clotting time (CT) essayed by ROTEM after recalcification, without added Tissue Factor (ExTem 20 µL), of citrated whole blood (300 µl) in presence or not of cells suspended in human albumin 5%. No coagulation is induced if absence of recalcification. Hepatocytes (white), hALPCs (black).

    Article Snippet: Measurements were performed on a ROTEM® delta analyser (Pentapharm, Munich, Germany).

    Techniques: Coagulation, Incubation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with human adult liver progenitor cells (hALPCs), hepatocytes, skin fibroblasts, bone marrow mesenchymal stem cells (BMMSC), bone marrow haematopoietic stem cells (BMHSC), or liver myofibroblasts suspended in human albumin 5% f as compared to control.

    Journal: PLoS ONE

    Article Title: Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity

    doi: 10.1371/journal.pone.0042819

    Figure Lengend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with human adult liver progenitor cells (hALPCs), hepatocytes, skin fibroblasts, bone marrow mesenchymal stem cells (BMMSC), bone marrow haematopoietic stem cells (BMHSC), or liver myofibroblasts suspended in human albumin 5% f as compared to control.

    Article Snippet: Measurements were performed on a ROTEM® delta analyser (Pentapharm, Munich, Germany).

    Techniques: Coagulation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) deficient in coagulation factors VII, V, X, and II (7d Pl, 5d Pl, 10d Pl, and 2d Pl, respectively) in presence of cells suspended in human albumin 5%. Human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to normal plasma f as compared to control.

    Journal: PLoS ONE

    Article Title: Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity

    doi: 10.1371/journal.pone.0042819

    Figure Lengend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of plasma (300 µl) deficient in coagulation factors VII, V, X, and II (7d Pl, 5d Pl, 10d Pl, and 2d Pl, respectively) in presence of cells suspended in human albumin 5%. Human adult liver progenitor cells (hALPCs) (black), control (albumin) (grey). * as compared to normal plasma f as compared to control.

    Article Snippet: Measurements were performed on a ROTEM® delta analyser (Pentapharm, Munich, Germany).

    Techniques: Coagulation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with or without hepatocytes suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control.

    Journal: PLoS ONE

    Article Title: Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity

    doi: 10.1371/journal.pone.0042819

    Figure Lengend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar). In contrast, enoxaparin (Eno) or Fondaparinux (Fond) was extemporaneously added to blood in contact with cells suspended in albumin. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) with or without hepatocytes suspended in human albumin 5%. Bivalirudin (Biva) or Hirudin (Hir) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control.

    Article Snippet: Measurements were performed on a ROTEM® delta analyser (Pentapharm, Munich, Germany).

    Techniques: Coagulation

    Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control $ as compared to bivalirudin Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control $ as compared to bivalirudin.

    Journal: PLoS ONE

    Article Title: Bivalirudin in Combination with Heparin to Control Mesenchymal Cell Procoagulant Activity

    doi: 10.1371/journal.pone.0042819

    Figure Lengend Snippet: Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of human adult liver progenitor cells (hALPCs) suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. hALPCs (black), Control (albumin) (grey). * as compared to hALPCs f as compared to control $ as compared to bivalirudin Clotting time (CT) assayed by ROTEM after recalcification, with added tissue factor (ExTem 20 µL) of citrated whole blood (300 µl) in presence or not of hepatocytes suspended in human albumin 5% with heparin (Hepar), enoxaparin (Eno), or fondaparinux (Fond) extemporaneously added to blood. Combination of anticoagulant drugs was obtained when bivalirudin (Biva) was extemporaneously added to blood. Hepatocytes (white), Control (albumin) (grey). * as compared to hepatocytes f as compared to control $ as compared to bivalirudin.

    Article Snippet: Measurements were performed on a ROTEM® delta analyser (Pentapharm, Munich, Germany).

    Techniques: Coagulation